Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Leap Therapeutics Inc LPTX

Healthcare Biotechnology
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic... see more

Recent & Breaking News (NDAQ:LPTX)

Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

PR Newswire January 3, 2020

Leap Therapeutics Reports Third Quarter 2019 Financial Results

PR Newswire November 14, 2019

Leap Therapeutics to Present at Upcoming Investor Conferences

PR Newswire September 4, 2019

Leap Therapeutics Reports Second Quarter 2019 Financial Results

PR Newswire August 9, 2019

Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update

PR Newswire July 25, 2019

Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital

PR Newswire July 11, 2019

Leap Therapeutics to Present at the 2019 Raymond James Life Sciences and MedTech Conference

PR Newswire June 11, 2019

Leap Therapeutics Reports First Quarter 2019 Financial Results

PR Newswire May 15, 2019

Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

PR Newswire April 3, 2019

Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

PR Newswire March 18, 2019

Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer

PR Newswire March 8, 2019

Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities

PR Newswire February 5, 2019

Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants

PR Newswire February 1, 2019

Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

PR Newswire January 31, 2019

Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer

PR Newswire January 14, 2019

Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer

PR Newswire December 14, 2018

Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results

PR Newswire November 9, 2018

Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting

PR Newswire November 9, 2018

Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress

PR Newswire October 21, 2018

Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress

PR Newswire October 8, 2018